ArticleInternational journal of clinical rheumatology2011
Pathophysiological mechanisms in antiphospholipid syndrome.
Article in International journal of clinical rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Digital decision support using a phospholipid-dependent biomarker for early exclusion of negative cases in lupus anticoagulant diagnostics.NPJ digital medicine · 2026Article
- Association between antivimentin/cardiolipin antibodies and pregnancy loss in pregnant women with at least one spontaneous miscarriage.BMC immunology · 2025Article
- Review
- Epigenetic Biomarkers in Thrombophilia-Related Pregnancy Complications: Mechanisms, Diagnostic Potential, and Therapeutic Implications: A Narrative Review.International journal of molecular sciences · 2024Review
- Septal atrial thrombosis as a primary presentation of antiphospholipid syndrome in a patient with ANA-negative systemic lupus erythematosus: a case report.Annals of medicine and surgery (2012) · 2024Article
- Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Review
- Reducing inappropriate inpatient thrombophilia testing through an electronic health record intervention.Proceedings (Baylor University. Medical Center) · 2023Article
- The role of monocytes in thrombotic diseases: a review.Frontiers in cardiovascular medicine · 2023Review
- COVID-19 and antiphospholipid antibodies.Best practice & research. Clinical haematology · 2022Review
- Essential laboratory tests for medical education.Academic pathology · 2022Article
- Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome.Journal of clinical medicine · 2021Review
- Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro.Auto- immunity highlights · 2020Article
- Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome.Journal of thrombosis and haemostasis : JTH · 2016Article
- An A1-A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome.The FEBS journal · 2015Article
- Article
- Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications.Clinical & developmental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antiphospholipid syndrome is a systemic autoimmune disease associated with thrombosis and recurrent fetal loss in the setting of detectable antiphospholipid (aPL) antibodies. The major antigenic target has been identifed as β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.